The findings from the Taffe and Dickerson labs underline the drug’s potential dangers.
“This easy approach is an entirely new way to turn a genetic defect off or on,” says Associate Professor Matthew Disney.
The LoGrasso lab’s “dual inhibitor”—two compounds in a single molecule—attacks a pair of proteins closely associated with development of Parkinson’s.
The findings from the Xiao lab could have medical applications from viral vaccines to treatments for autoimmune diseases.